Avalo Therapeutics (AVTX) Common Equity (2014 - 2026)
Avalo Therapeutics (AVTX) posted Common Equity of $68.3 million for Q1 2026, down 17.74% on a QoQ basis from $83.0 million in Q4 2025, and down 44.28% year-over-year from $122.6 million in Q1 2025.
Avalo Therapeutics (AVTX) Common Equity (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Common Equity history runs 13 years deep, the most recent figure standing at $68.3 million for Q1 2026.
- Quarterly Common Equity fell 44.28% year-over-year to $68.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.3 million (down 44.28% YoY) and the FY2025 annual result came in at $83.0 million, down 37.57% from the prior year.
- Common Equity was $68.3 million for Q1 2026 at Avalo Therapeutics, down from $83.0 million in the prior quarter.
- Across five years, Common Equity topped out at $133.0 million in Q4 2024 and bottomed at -$112.5 million in Q1 2024.
- A 5-year average of $29.1 million and a median of $7.3 million in 2023 frame the typical range for Common Equity.
- Peak annual rise in Common Equity reached 1721.36% in 2024, while the deepest fall reached 1695.79% in 2024.
- Avalo Therapeutics' Common Equity stood at -$10.9 million in 2022, then jumped by 166.92% to $7.3 million in 2023, then jumped by 1721.36% to $133.0 million in 2024, then plunged by 37.57% to $83.0 million in 2025, then declined by 17.74% to $68.3 million in 2026.
- Business Quant data shows AVTX's Common Equity at $68.3 million in Q1 2026, $83.0 million in Q4 2025, and $91.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 68.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.32 Mn |
| Dec 31, 2025 | 83.05 Mn |
| Sep 30, 2025 | 91.55 Mn |
| Jun 30, 2025 | 104.57 Mn |
| Mar 31, 2025 | 122.62 Mn |
| Dec 31, 2024 | 133.03 Mn |
| Sep 30, 2024 | 21.08 Mn |
| Jun 30, 2024 | -13.61 Mn |
| Mar 31, 2024 | -112.54 Mn |
| Dec 31, 2023 | 7.30 Mn |
| Sep 30, 2023 | 14.70 Mn |
| Jun 30, 2023 | -6.97 Mn |
| Mar 31, 2023 | -6.27 Mn |
| Dec 31, 2022 | -10.92 Mn |
| Sep 30, 2022 | -2.03 Mn |
| Jun 30, 2022 | -5.95 Mn |
| Mar 31, 2022 | 6.34 Mn |
| Dec 31, 2021 | 23.08 Mn |
| Sep 30, 2021 | 40.31 Mn |
| Jun 30, 2021 | 21.59 Mn |